April 2014
Volume 55, Issue 13
ARVO Annual Meeting Abstract  |   April 2014
Preclinical Evaluation of ENV515 (travoprost) Intracameral Implant - Clinical Candidate for Treatment of Glaucoma Targeting Six-Month Duration of Action
Author Affiliations & Notes
  • Tomas Navratil
    Envisia Therapeutics, Research Triangle Park, NC
  • Andres Garcia
    Envisia Therapeutics, Research Triangle Park, NC
  • Janet Tully
    Envisia Therapeutics, Research Triangle Park, NC
  • Benjamin Maynor
    Envisia Therapeutics, Research Triangle Park, NC
  • Iqbal Ike K Ahmed
    University of Toronto, Toronto, ON, Canada
  • Donald L Budenz
    University of North Carolina, Chapel Hill, NC
  • Richard A Lewis
    Sacramento Eye Consultants, Sacramento, CA
  • Steven L Mansberger
    Devers Eye Institute, Portland, OR
  • Brian C Gilger
    North Carolina State University, Raleigh, NC
  • Benjamin R Yerxa
    Envisia Therapeutics, Research Triangle Park, NC
  • Footnotes
    Commercial Relationships Tomas Navratil, Envisia Therapeutics (E); Andres Garcia, Envisia Therapeutics (E); Janet Tully, Envisia Therapeutics (E); Benjamin Maynor, Envisia Therapeutics (E); Iqbal Ike Ahmed, Envisia Therapeutics (C); Donald Budenz, None; Richard Lewis, Envisia Therapeutics (C); Steven Mansberger, Envisia Therapeutics (C); Brian Gilger, Envisia Therapeutics (C); Benjamin Yerxa, Envisia Therapeutics (E)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 3548. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Tomas Navratil, Andres Garcia, Janet Tully, Benjamin Maynor, Iqbal Ike K Ahmed, Donald L Budenz, Richard A Lewis, Steven L Mansberger, Brian C Gilger, Benjamin R Yerxa; Preclinical Evaluation of ENV515 (travoprost) Intracameral Implant - Clinical Candidate for Treatment of Glaucoma Targeting Six-Month Duration of Action. Invest. Ophthalmol. Vis. Sci. 2014;55(13):3548.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Prostaglandin analogues (PGA) are the most prescribed class of therapies for glaucoma in the US but possess several shortcomings: low adherence, hyperemia, and fluctuation in ocular drug levels and intraocular pressure (IOP). The purpose of this work was to evaluate the efficacy, duration of action, and safety/tolerability of the ENV515 (travoprost) Intracameral Implant experimental therapy prior to further preclinical and clinical development. ENV515 is a biodegradable polymer drug delivery system using an extended release formulation of the PGA travoprost. ENV515 is being developed with the aim to address the shortcomings of the topical PGA therapies.


We used PRINT® technology to fabricate ENV515 to fit the anatomy of the human iridocorneal angle and allow administration via acceptably-sized needle. We used hypertensive and normotensive Beagle dogs using a modified McDonald-Shadduck scale to evaluate safety and tolerability over a period of 24 weeks in vivo. The in vivo location of the implant was imaged via anterior chamber OCT and Gonioscopy exams. IOP was evaluated in non-sedated animals.


In vitro, the extended release of travoprost from ENV515 occurred over a period of 180 days. The implant administrations were conducted in Beagle dogs by intracameral injections via a custom injector and resulted in 100% success rate for implant delivery. Gonioscopy and anterior chamber OCT imaging showed stability without movement in the iridocorneal angle in hypertensive Beagle dogs (Figures 1 and 2). The baseline IOP in hypertensive Beagle dog study was 23.4±1.0 mmHg (mean±SEM, n=6 eyes). The mean decrease in intraocular pressure was 7.2±0.5 mmHg or 30±2% change from baseline IOP over 24 week treatment period (p<0.001). Only minor and transient ocular irritation occurred due to the insertion procedure. Notably, there was lower incidence of hyperemia compared to topical TRAVATAN Z. Similar outcomes were observed in a replicatory study in normotensive Beagle dogs.


ENV515 demonstrated robust, sustained IOP-lowering effect for 24 weeks following single implantation via intracameral injection with acceptable safety and tolerability in hypertensive and normotensive Beagle dogs. ENV515 preclinical safety and tolerability profile supports advancing ENV515 into clinical studies in glaucoma patients.

Keywords: 568 intraocular pressure • 608 nanomedicine • 420 anterior chamber  

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.